Bi-weekly: Thursdays, 12 pm EDT/EST, 9 am PT/PST, 5 pm BST/BDT, 6 pm CEST/CET
https://dfci.zoom.us/webinar/register/WN_m7JJaw52T8yZYt8-ykL6UQ
Some seminars were recorded and accessible for a limited time on our youtube channel.
Upcoming Speakers
September 25th, 2025
Host: Hubert Huang
Ed Tate
GSK Chair in Chemical Biology, Imperial College & Francis Crick Institute
Chemical biology for drug discovery: proximity-induced pharmacology and ADC payloads
Ed holds the GSK Chair in Chemical Biology at Imperial College London, and he is a Group Leader at the Francis Crick Institute. Following his PhD (2000) with Steve Ley in Cambridge and postdoctoral research in Paris as an 1851 Fellow and Howard Trust Fellow, he was awarded a BBSRC David Phillips Fellowship in 2006 to start his group at Imperial College. He sits on the advisory boards of several international research institutes and biotechs, and develops new drug discovery technologies with companies including Pfizer, GSK and AstraZeneca. His research has been recognised by awards and Fellowships, most recently the 2019 Sir David Cooksey Translation Prize, the 2020 Corday-Morgan Prize of the RSC, a 2022 Cancer Research UK Programme Award, and the 2024 RSC Horizon Prize. In 2023 he was appointed to the GSK Endowed Chair in Chemical Biology at Imperial College. Ed is also academic founder of several companies developing his lab’s research toward clinical applications, including Siftr Bio and Myricx Bio, which in 2024 raised one of the largest Series A rounds to date for a European biotech.
October 9th, 2025
Host: Zuzanna Kozicka
Dual E3 ligase recruitment by monovalent degraders enables redundant and tuneable degradation of SMARCA2/4.
​
Alejandro Correa-Sáez
Centre for Targeted Protein Degradation, University of Dundee​
Alejandro Correa-Sáez has been a Postdoctoral Research Fellow at the Centre for Targeted Protein Degradation (CeTPD), University of Dundee, since 2023, under the supervision of Professor Alessio Ciulli. He obtained his PhD in Biomedicine from the University of Córdoba (Spain) in 2022. Currently supported by a Marie SkÅ‚odowska-Curie Fellowship through UKRI,his research focuses on developing novel strategies for the rational design of molecular glues. His broader scientific interests include understanding native mechanisms of protein regulation to guide the design of more effective degraders, as well as exploring how protein degraders can be leveraged to study and characterize cell signalling pathways.
Dmitri Segal
AITHYRA Research Institute​
Dmitri Segal is a biomedical researcher interested in understanding how innovative pharmacological strategies can be used to reprogram cancer cells. He obtained his PhD at the University of Toronto under the supervision of Mikko Taipale. He is now a postdoctoral fellow at the AITHYRA Research Institute for Biomedical Artificial Intelligence working in the laboratory of Georg Winter. Here, Dmitri is focused on developing and using proximity inducing pharmacology to regulate and rewire transcriptional circuits in cancer. He also utilizes several genomic screening approaches for characterizing the mechanism-of-action of small molecule degraders to help expand the molecular strategies available for targeted protein degradation.
​
Valentina Spiteri
Centre for Targeted Protein Degradation, University of Dundee​
Valentina Spiteri is a structural biologist and biophysicist post-doctoral researcher at the Centre for Targeted Protein Degradation (CeTPD) at the University of Dundee. She is interested in leveraging integrative approaches to unravel novel degrader mechanisms and guide their design. She joined CeTPD in 2021 following the completion of her PhD at University College London. In her time at the CeTPD her primary role has been to work across several collaborative projects with industrial partners including with Boehringer Ingelheim and currently with Eisai with an aim to develop degraders as clinical candidates.
​
​
Yunan Zheng
Technology and Therapeutic Platforms, Small Molecule Therapeutics & Platform Technologies, AbbVie
A cellular approach to evaluate E3 ligases for use in TPD
Yunan Zheng earned her PhD in 2018 under Dr. Abhishek Chatterjee, where her research centered on unnatural amino acid incorporation. After graduation, she joined AbbVie’s chemical biology group, dedicating her efforts to developing and implementing novel chemical biology approaches. In 2021, she transitioned to AbbVie’s targeted protein degradation group, continuing her passion for leveraging innovative technologies to address challenging biological questions and advance drug discovery.
​
​
October 23th, 2025
Host: Mikolaj Slabicki
Amit Choudhary
Brigham & Women’s Hospital and the Broad Institute
A Scalable Design for Proximity-Inducing Molecules
Amit is an Assistant Professor of Medicine at Harvard Medical School with appointments at the Brigham & Women’s Hospital and the Broad Institute. He performed his predoctoral studies at the Indian Institute of Science‒Bangalore (IISc), working on organic synthesis and protein folding. In 2006, he moved to Univ. of Wisconsin‒Madison to pursue his graduate studies, where he discovered a force that is akin to the hydrogen bond in its quantum mechanical origin and widespread prevalence in biomolecules. In 2011, Amit was elected as a Harvard Junior Fellow and hosted by Prof. Stuart Schreiber at the Broad Institute. Here, he shifted his research focus from quantum mechanical interactions to the development of broadly applicable technologies inspired by specific problems in infectious disease and diabetes. The efforts of Amit’s group have been recognized by Burroughs Wellcome Fund’s Career Award at the Scientific Interface, NIH Director’s Transformative Research Award, DARPA’s SAFE GENES and HEALR awards, Vilcek Prize for Creative Promise, and ICBS Young Chemical Biologist Award. Intellectual property emerging from the Choudhary lab has been licensed to several genome editing companies and Amit is the scientific founder of Photys Therapeutics that leverages the group’s findings on protein editing.